Literature DB >> 15106095

Incremental effectiveness of 2 doses of measles-containing vaccine compared with 1 dose among high school students during an outbreak.

Tracey V Lynn1, Michael Beller, Elizabeth A Funk, John P Middaugh, Donald Ritter, Paul A Rota, William J Bellini, Thomas J Torok.   

Abstract

A measles outbreak occurred among a highly vaccinated population in Alaska during 1998, providing an opportunity to determine the incremental efficacy of >or=2 doses of measles-containing vaccine (MCV) compared with 1 dose. Of 33 confirmed case patients identified, 31 had been vaccinated with 1 dose of MCV, 1 had received 2 doses, and vaccination status was unknown in 1 case. Seventy percent of cases were school-associated; 58% of cases occurred in 2 high schools. Of 3679 students attending the 2 schools, 50.4% and 45.5% had received >or=2 doses of MCV before measles introduction at the schools. The relative risk of developing measles among persons vaccinated with >or=2 doses of MCV compared with 1 dose was 0.06 (95% confidence interval, 0.01-0.44; P<.001), yielding an estimated incremental vaccine efficacy of 94.1% (95% confidence interval, 55.9%-99.2%; P<.001). Rapid implementation of a mandatory second-dose MCV requirement probably limited the extent of this outbreak.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106095     DOI: 10.1086/377699

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population.

Authors:  Michiel van Boven; Mirjam Kretzschmar; Jacco Wallinga; Philip D O'Neill; Ole Wichmann; Susan Hahné
Journal:  J R Soc Interface       Date:  2010-04-14       Impact factor: 4.118

2.  Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease.

Authors:  Freddy Caldera; Elizabeth Ann Misch; Sumona Saha; Arnold Wald; Youqi Zhang; Jeffrey Hubers; Bryant Megna; Dana Ley; Mark Reichelderfer; Mary S Hayney
Journal:  Dig Dis Sci       Date:  2018-10-13       Impact factor: 3.199

3.  Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII.

Authors:  Barbara J Kuter; Gary S Marshall; Jaime Fergie; Elvira Schmidt; Manjiri Pawaskar
Journal:  Hum Vaccin Immunother       Date:  2022-02-07       Impact factor: 3.452

4.  Epstein-Barr virus but not cytomegalovirus is associated with reduced vaccine antibody responses in Gambian infants.

Authors:  Beth Holder; David J C Miles; Steve Kaye; Sarah Crozier; Nuredin Ibrahim Mohammed; Nancy O Duah; Elishia Roberts; Olubukola Ojuola; Melba S Palmero; Ebrima S Touray; Pauline Waight; Matthew Cotten; Sarah Rowland-Jones; Marianne van der Sande; Hilton Whittle
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

5.  Cytomegalovirus infection induces T-cell differentiation without impairing antigen-specific responses in Gambian infants.

Authors:  David J C Miles; Mariama Sanneh; Beth Holder; Sarah Crozier; Samuel Nyamweya; Ebrima S Touray; Melba S Palmero; Syed M A Zaman; Sarah Rowland-Jones; Marianne van der Sande; Hilton Whittle
Journal:  Immunology       Date:  2008-01-11       Impact factor: 7.397

Review 6.  Eradication of measles: remaining challenges.

Authors:  Heidemarie Holzmann; Hartmut Hengel; Matthias Tenbusch; H W Doerr
Journal:  Med Microbiol Immunol       Date:  2016-03-02       Impact factor: 3.402

7.  Estimating the nationwide transmission risk of measles in US schools and impacts of vaccination and supplemental infection control strategies.

Authors:  Parham Azimi; Zahra Keshavarz; Jose Guillermo Cedeno Laurent; Joseph G Allen
Journal:  BMC Infect Dis       Date:  2020-07-11       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.